艾塞那肽治疗不同体质量指数的2型糖尿病患者的观察

目的观察艾塞那肽对不同体质量指数（BMI）的2型糖尿病患者的疗效及安全性。方法62例经口服降糖药物治疗而血糖控制不佳（HbAlC〉17．0％）的2型糖尿病患者，依据BMI分为3组，A组（正常组，19≤BMI〈24），B组（超重组，24≤BMI〈28），C组（肥胖组，BMIt〉28）。3组均加用艾塞那肽。12周后比较3组治疗前、后糖化血红蛋白（HbA1C）、空腹血糖（FPG）、餐后2h血糖（2hPG）、血脂、体质量、收缩压（SBP）、舒张压（DBP）的变化，记录低血糖发生的次数及不良反应。结果3组患者HbAlC、FPG、2hPG、血甘油三酯（TG）与治疗前相比均有明显降低（P〈0．01），血高密度脂蛋白胆固醇（HDL—C）较治疗前明显升高（P〈0．05），B组及C组体质量、BMI与治疗前相比也有明显下降（分别为P〈0．05，P〈0．01），同时两组SBP、DBP也有显著降低（P〈0．05）。结论艾塞那肽更适用于超重及肥胖的2型糖尿病患者。

Clinical research on efficacy of exenatide in type 2diabetes patients

Objective To research the efficacy and safty of exenatide in type 2 diabetes patients with different body mass index（BMI）. Methods Totally 62 patients with type 2 diabetes treated with oral antidiabetic drugs and with inade- quately glucose controlled were enrolled. These patients were selected and randomized into 3 groups by BMI, group A（ 19 BMI 〈 24）, group B （24 ≤ BMI 〈 28 ）, group C （ BMI ≥28 ）. All patients received exenatide for 12 weeks without chan- ging their basal therapy. Before treatment and after glycated hemoglobin A1 c （HbAlc）, fasting plasma glucose （FPG）, postprandial 2 h plasma （ 2 hPG ）, total cholesterol （ TC ） , triglycolides （ TG ） , weight, systolic blood pressure （ SBP）, diatolic blood pressure （DBP） were measured and compared. Results In 3 groups HbA1 c, FPG,2hPG, TG were all significantly decreased（P 〈0. 05）,HDL- C were significantly increased（P 〈0. 05）. In group B and C weight,BMI were reduced significantly（ P 〈 0. 05,P 〈 0. 01 ）, and SBP, DBP were decreased （ P 〈 0. 05 ）. Conclusion The therapy with exenatide is more suitable for overweight and obese tyoe 2 diabetic patiens.